Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses.
Nayyerabadi M, Fourcade L, Joshi SA, Chandrasekaran P, Chakravarti A, Massé C, Paul ML, Houle J, Boubekeur AM, DuSablon C, Boudreau V, Bovan D, Darbinian E, Coleman EA, Vinci S, Routy JP, Hétu PO, Poudrier J, Falcone EL. Nayyerabadi M, et al. Among authors: bovan d. Int J Infect Dis. 2023 Nov;136:136-145. doi: 10.1016/j.ijid.2023.09.006. Epub 2023 Sep 17. Int J Infect Dis. 2023. PMID: 37717649 Free article.
Non-severe hypoglycemia in type 1 diabetes: a randomized crossover trial comparing two quantities of oral carbohydrates at different insulin-induced hypoglycemia ranges.
Taleb N, Gingras V, Cheng R, Parent V, Messier V, Bovan D, Shohoudi A, Brazeau AS, Rabasa-Lhoret R. Taleb N, et al. Among authors: bovan d. Front Endocrinol (Lausanne). 2023 Jun 2;14:1186680. doi: 10.3389/fendo.2023.1186680. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37334295 Free PMC article. Clinical Trial.
Melanoma Cell Reprogramming and Awakening of Antitumor Immunity as a Fingerprint of Hyper-Harmonized Hydroxylated Fullerene Water Complex (3HFWC) and Hyperpolarized Light Application In Vivo.
Markelić M, Mojić M, Bovan D, Jelača S, Jović Z, Purić M, Koruga D, Mijatović S, Maksimović-Ivanić D. Markelić M, et al. Among authors: bovan d. Nanomaterials (Basel). 2023 Jan 17;13(3):372. doi: 10.3390/nano13030372. Nanomaterials (Basel). 2023. PMID: 36770334 Free PMC article.
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
McInnes N, Hall S, Hramiak I, Sigal RJ, Goldenberg R, Gupta N, Rabasa-Lhoret R, Braga M, Woo V, Sultan F, Otto R, Smith A, Sherifali D, Liu YY, Gerstein HC; REMIT-sita Collaborative Group. McInnes N, et al. Diabetes Care. 2022 Jan 1;45(1):178-185. doi: 10.2337/dc21-0278. Diabetes Care. 2022. PMID: 34728531 Clinical Trial.